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Axial symptoms emerge in a significant proportion of patients with Parkinson’s disease
(PD) within 5 years of deep brain stimulation (STN-DBS). Lowering the stimulation
frequency may reduce these symptoms. The objectives of the current study were
to establish the relationship between gait performance and STN-DBS frequency in
chronically stimulated patients with PD, and to identify factors underlying variability in
this relationship. Twenty-four patients treated chronically with STN-DBS (>4 years) were
studied off-medication. The effect of stimulation frequency (40–140Hz, 20 Hz-steps,
constant energy) on gait was assessed in 6 sessions spread over 1 day. Half
of the trials/session involved walking through a narrow doorway. The influence of
stimulation voltage was investigated separately in 10 patients. Gait was measured
using 3D motion capture and axial symptoms severity was assessed clinically. A
novel statistical method established the optimal frequency(ies) for each patient by
operating on frequency-tuning curves for multiple gait parameters. Narrowly-tuned
optimal frequencies (20Hz bandwidth) were found in 79% of patients. Frequency change
produced a larger effect on gait performance than voltage change. Optimal frequency
varied between patients (between 60 and 140Hz). Contact site in the right STN and
severity of axial symptoms were independent predictors of optimal frequency (P =
0.009), with lower frequencies associated with more dorsal contacts and worse axial
symptoms. We conclude that gait performance is sensitive to small changes in STN-DBS
frequency. The optimal frequency varies considerably between patients and is associated
with electrode contact site and severity of axial symptoms. Between-subject variability
of optimal frequency may stem from variable pathology outside the basal ganglia.
Keywords: parkinson’s disease, gait, deep brain stimulation, subthalamic nucleus, axial symptoms
Di Giulio et al. Optimizing DBS for Parkinsonian Gait
INTRODUCTION
Axial symptoms, consisting of gait, balance and speech problems,
are a serious and disabling feature of Parkinson’s disease
(PD). These symptoms can emerge in a significant proportion
of patients (20–80%) who have been receiving deep brain
stimulation of the subthalamic nucleus (STN-DBS) for up to
5 years (1–10). There is some evidence that the symptoms
might be better controlled using low stimulation frequencies of
60–80Hz rather than the higher frequencies of around 130Hz
that typically are implemented soon after implantation (11–14).
However, not all studies have shown this effect of lowering
the stimulation frequency (15, 16), suggesting there might be
substantial heterogeneity within the PD population. The aim
of this study was to measure the response to change in DBS
stimulation parameters in individual patients with PD. We
focused on changes in stimulation frequency, but undertook an
additional experiment to investigate the relative effects of the
stimulation voltage change that inevitably accompany frequency
change when using a constant-energy stimulation protocol.
It is not understood why axial symptoms emerge in only some
patients receiving STN-DBS, and why the axial symptoms in
those patients might respond variably to stimulation frequency.
To shed light on this we have identified, for the first time,
the stimulation-frequency tuning curves and their confidence
intervals for one aspect of motor behavior in individual PD
patients who had been chronically stimulated for more than 4
years. The behavior we have chosen is gait, since gait difficulties
represent an important component of the axial symptom
complex. By ascertaining the frequency-tuning characteristics
related to gait performance for individuals, we have been able to
establish the variability of tuning within a chronically stimulated
PD cohort and to identify some of the factors underlying this
variability. This has enabled us to speculate on the potential
role of lesions outside the basal ganglia on the emergence of
axial symptoms.
MATERIALS AND METHODS
Participants
Twenty-four PD patients (8 female) were recruited from the
National Hospital for Neurology and Neurosurgery. Patients
were eligible for the study if they had been implanted with STN-
DBS 4 years or more before the test date and they could walk
independently indoors. Patients with a known cognitive deficit
were not recruited. Patients’ clinical details and stimulation sites
are reported in Table 1. Participants gave written, informed
consent to the procedures, which conformed to the Declaration
of Helsinki and were approved by the University College London
Hospital NHS Trust ethics committee (13/LO/0379).
Experimental Procedure
Patients visited the laboratory after at least 12 h of medication
(levodopa + dopamine agonist) wash-out. The STN-DBS
Abbreviations: PD, Parkinson’s disease; DBS, deep brain stimulation; PPN,
pedunculopontine nucleus; STN, subthalamic nucleus; UPDRS, Unified
Parkinson’s disease rating scale.
parameters were set, with patients blinded to the setting, and
a 30-min “stabilization” time was observed before each test
session, which lasted 20min. A visit included tests of gait function
and upper-limb function (not reported here), and a clinical
assessment of axial symptoms using a reduced version of the
UPDRS-III test (rising from a chair, posture, gait and pull test).
The gait protocol consisted of walking 8m per trial for 16
trials at each STN-DBS setting. Some patients completed fewer
trials for some settings, but never less than 8 trials, which was
deemed adequate to be included in the analysis (patient OP18
completed 12 trials at 120Hz; 8 trials were completed at 40Hz
for patients OP04, OP13, and OP22; at 60Hz for patients OP08,
OP21, and OP22; at 80Hz for patient OP22; at 140Hz for
patients OP08, OP16, and OP18). At the beginning of half the
trials selected randomly, a mock doorway was placed halfway
along the walkway. The doorway consisted of two motor-driven,
300 mm-wide, floor-to-ceiling panels separated by a gap set
to the patient’s shoulder width. An auditory tone instructed
patients to start walking at their preferred pace and manner.
Gait performance was measured from infra-red markers placed
bilaterally on the second metatarsal head and the heel. Marker
positions were collected by a 6-unit motion capture system
(CODA CX1; Charnwood Dynamics, Rothley, UK) at 100Hz.
Experiment 1
Six experimental sessions were attempted during a single visit to
study the effect of stimulation frequency. In each session STN-
DBS frequency was changed in a random order. The range tested
was 40–140Hz with 20 Hz-steps, adjusting voltage stimulation in
order to maintain the stimulation energy constant, according to
the formula,
Energy(TEED) =
voltage2 × pulse width× frequency
impedance
At the end of this experiment, the patients returned to their
normal medication regime and DBS settings.
Experiment 2
In experiment 1 each change in stimulation frequency was
accompanied by a voltage change to maintain constant
stimulation energy. We therefore undertook an additional
experiment to ascertain which of these two stimulation
parameters had the greater effect on gait performance. The
relative influence of frequency and voltage change was studied
in a subset of 12 patients in a separate visit (median 338 days
after experiment 1; range 2–539 days). The gait protocol was
performed using four stimulation settings in random order (four
sessions), combining two voltages at each of two stimulation
frequencies (80 and 120Hz). These stimulation frequencies were
chosen because they represent typical low and high frequencies
used clinically and they were best tolerated by the patients during
experiment 1. The voltage levels were determined using the
constant energy criterion for the high-frequency/low-voltage and
low-frequency/high-voltage combinations. Because voltage was
determined by frequency and constant energy, voltage levels were
different across patients. The mean voltage difference between
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low and high setting was 0.82V. Two patients completed only 3
sessions and were excluded from the analysis.
Measurements
Stepping events were determined for each trial using custom
scripts in Matlab (Mathworks, Natik, US). Local minima were
identified on the antero-posterior heel and toe acceleration traces
and classified as heel strikes and toe offs. These were visually
inspected together with the markers’ vertical positions, and
manually adjusted if needed, via an interactive program (17, 18).
These events were used to calculate gait performance variables,
including stride length (distance in heel antero-posterior position
between heel strike of one foot and next heel strike of the same
foot), stride velocity (stride length divided by stride duration),
normalized double-support time (time between heel strike of one
foot to subsequent toe off of the opposite foot as a percentage
of the time between left and right heel strikes), and step-length
asymmetry using the following formula (19)
Asymmetry = 100×
∣∣∣∣ln
(
left step length
right step length
)∣∣∣∣
where step length is the antero-posterior distance between feet at
their respective heel strikes.
Statistical Analysis
Single Participant Analysis
For each participant, tuning curves relating STN-DBS frequency
(40–140Hz) to each gait variable measured over multiple
stride cycles from Door and No-Door trials separately were
constructed. An ANOVA multiple comparison test with STN-
DBS frequency as a factor was performed on each gait variable.
This utilized Matlab’s multcompare function with a Tukey’s
honest significant difference criterion in which non-overlapping
confidence intervals indicated a significant difference (P <
0.05) between any pair of frequencies, thus identifying the
best and non-separable STN-DBS frequencies for each gait
variable for each patient. Better performance was indicated by
higher values of stride velocity and length, and lower values
of normalized double-support time and step-length asymmetry.
Each patient’s overall optimal STN-DBS frequencies were defined
as the frequencies that were common to the best frequencies for
each gait variable and both door conditions.
Group Analysis
These statistical tests were performed using SPSS (IBM SPSS
ver.24). The Wilcoxon signed-rank test was used to compare the
relative effectiveness of frequency vs. voltage, and to compare
clinical postural scores at the time of the current test relative
to post-surgery follow-up (measured off medication). Because
identical STN-DBS frequencies were not always available when
comparing scores at post-surgery (original frequency) with scores
on the test day (test frequency) some corrections were adopted.
If the original frequency was 130Hz, the clinical score was
compared with the mean measured at 140 and 120Hz test
frequencies during the experimental session. If the original
frequency was above 140Hz, the clinical score was compared
with the one measured at 140Hz test frequency.
The correlation between optimal frequency and clinical
score was assessed using the non-parametric Spearman’s rank
correlation coefficient (rs). When a patient had more than one
optimal frequency, the mean clinical score at those frequencies
was paired with the mean optimal frequency.
Multiple regression with three factors (clinical score, right
electrode site, left electrode site) as predictors of optimal
frequency was performed using a forward stepwise method.
Clinical scores were measured on the test day with the original
stimulation frequency (as above). The left and right sites of the
active electrode were determined as follows. The stereotactic
coordinates of the center of each active contact were identified on
an intra-operative stereotactic MRI scan (T2 weighted) acquired
immediately following lead implantations. The coordinates were
then superimposed onto the pre-implantation stereotactic T2-
weightedMRI scan (20). From these images, the electrode contact
locations were allocated to five regions of the STN (superior,
postero-lateral, central, inferior, and antero-medial). Unipolar
stimulation contacts in the superior and postero-lateral sites
were merged to represent the dorsal region, and inferior and
antero-medial sites were merged to represent ventral regions.
An intermediate central region consisted solely of central sites.
Bipolar stimulation sites were included in the analysis if both
contacts were situated in the same merged region (left n = 2;
right n = 2). If the two contacts were in different regions or if
imaging was not available, they were designated as missing data
(left n = 3; right n = 2). The regression data were subjected
to automatic preparation, which trimmed outliers, replaced
missing values and merged categories to maximize association
with the target optimal frequency. The Akaike information
criterion was used for entry/removal of a predictor from
the model.
RESULTS
All patients tried to complete the tests at each of the six
stimulation frequencies. However, patients and their carers were
reminded that they could withdraw from a setting if it was too
uncomfortable and not tolerable. Not all patients were able to
tolerate the six stimulation frequencies, 40Hz being the least
well-tolerated. Six frequencies were completed by 11 patients, five
by 8 patients, four by 4 patients, and three by 1 patient. However,
this was deemed acceptable because we aimed to analyse each
patient individually. If a frequency was not tolerated, clearly that
frequency could not be considered as potentially optimal for
that patient.
The four variables chosen to represent gait performance were
not equally sensitive to changes of stimulation frequency. Stride
velocity was themost discriminatory variable (11 patients showed
a single best frequency), followed by stride length (9 patients),
double-support time (3 patients), and step-length asymmetry
(2 patients). Reliance on just one gait variable was deemed
insufficient to determine an optimal frequency per patient as it
was important to ensure that a frequency that worked well for
one gait variable was not detrimental to any others.We developed
a common-frequency algorithm that included information from
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FIGURE 1 | Tuning curves used to find the optimum STN-DBS frequency for
gait in a representative patient. Mean values and confidence intervals used in
the multcompare test from all strides performed by patient OP11 according to
the six STN-DBS frequencies. Data shown separately for No-Door (left
column) and Door (right column) conditions. Gait performance variables from
top are stride velocity, stride length, normalized double-support and
step-length asymmetry. Statistically, two frequencies were different when the
plotted confidence interval did not overlap. For each variable, the statistical
test was run and one or more best frequencies were identified (black circles).
The optimal frequency band was defined as those best frequencies that were
common to all gait variables in both the Door and No-Door condition (framed
black circles). For this patient, the optimum frequency was 80Hz.
all four measured variables and their tuning curves under both
Door and No-Door walking conditions (Figure 1).
Figure 2 shows the result of applying this common-frequency
method to all patients individually. The method was able to
identify a single optimal frequency for 19 patients. It was unable
to distinguish between two frequencies in 3 patients and three
frequencies in 2 patients. Every frequency studied, with the
exception of 40Hz, was designated as optimal for at least one
patient (Figure 2). Of these, 60Hz was the least represented
frequency (n= 1) while 80Hz was the most represented (n= 11).
Frequency vs. Voltage
To investigate whether stimulation frequency or voltage was
more important for altering gait performance, a sub-set of
FIGURE 2 | Within-group distribution of optimum STN-DBS frequencies for
gait. The optimum frequencies (black squares) are shown among those
studied (gray squares) and those not studied (white squares) for each patient,
using the method described in Figure 1. Bar chart below indicates the
number of patients for which a frequency was optimal.
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patients were studied under four stimulation conditions using
2 frequencies (80 and 120Hz) and two voltages (high and low).
This reduced protocol was adopted in order to test the relative
effect of stimulation frequency and voltage within the same
patients. Although our results are based on ten patients and four
conditions only, we observed that the four data points obtained
for each variable from the four conditions can be arranged
differently to show either the mean effect of voltage or the
mean effect of frequency, as shown for one patient (Figure 3A).
For the group (Figure 3B), the mean effect of frequency was
reliably larger than the mean effect of voltage for 3 of the 4 gait
variables (Wilcoxon: stride velocity, P = 0.047; stride length, P =
0.028; double-support time, P = 0.013; step-length asymmetry,
P = 0.445).
Axial Symptoms
The severity of gait and postural symptoms and their
deterioration over the period of implantation was estimated from
the reduced UPDRS score shown in Table 2. For the group, there
was a trend for deterioration in clinical scores when comparing
the patient post-surgery (original) and at test day with frequency
set as close as possible to original (Wilcoxon between columns
A and J in Table 2, P = 0.060). At the time of the current test
session (i.e., Experiment 1), comparing scores measured at the
best gait frequency (from columns C-H at frequency in I) and the
scores measured at the frequency set at post-surgery follow-up
(column J, from columns C-H in bold, i.e., frequency in B),
the gait and postural symptoms were significantly better when
stimulating at the best gait frequency identified in this study
compared to the original frequency (Wilcoxon, P = 0.010).
The current severity of gait and postural symptoms (at original
frequency, column J) was inversely correlated with the optimal
frequency for gait (column I, rs = −0.410, P = 0.047). Over the
period of implantation, the rate of change of clinical score (at
original frequency, column L) also was inversely correlated with
the optimal stimulation frequency (rs = −0.417, P = 0.043).
Thus, those patients with more severe and/or faster deteriorating
symptoms, measured with the clinical score, tended to optimize
at a lower stimulation frequency at the time of testing.
Site of Stimulation
Figure 4 shows each patient’s optimum frequency for gait and
their corresponding site of stimulation in the right and left
STN divided into 5 regions. After merging these data into
dorsal, central and ventral regions, and combining the right
and left sides, a relationship between stimulation site and
optimal frequency emerged. The median optimal stimulation
frequency was significantly lower for the dorsal (90Hz) than
the ventral (120Hz) sites (independent samples median test, P
= 0.001). The median frequency in the central region (100Hz)
was intermediate.
Dependence of Optimal Frequency on
Axial Symptoms and Site of Stimulation
Because of the relationships between optimal frequency and both
clinical score (current score at the original stimulation frequency)
and stimulation site, we subjected the data to a multiple
FIGURE 3 | Comparison of relative effects of changing frequency and voltage
on gait variables. (A) Representative patient’s mean stride velocity data at each
of four STN-DBS settings. The same data are arranged differently to show the
mean effect of changing voltage (left) and the mean effect of changing
frequency (right). For this patient, the change in stride velocity was larger when
changing frequency from 120 to 80Hz compared to a change in voltage from
a high (4.3 and 5.2 V left and right electrodes respectively) to a low value (3.5
and 4.2V left and right electrode respectively). (B) All patients’ frequency
(1Freq) and voltage (1Volt) effects for each gait variable. The change due to
1Freq was significantly (p < 0.05) larger than the change due to 1Volt for
stride velocity, stride length and double-support time.
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FIGURE 4 | Relationship between electrode contact position and the optimal frequency for gait. Each patient’s active contact location within five regions of STN is
shown separately for their right and left electrodes. Only patients with monopolar stimulation are reported (right STN, n = 20; left STN, n = 19). The optimal frequency
for gait is denoted by the position of the circle on the y-axis and by a color code (blue 60 Hz, green 80 Hz, yellow 100 Hz, orange 120 Hz, red 140 Hz). If more than
one optimal STN-DBS frequency was found, the circle is split into two or three color-coded sections and its position on the y-axis is the mean of those frequencies.
regression analysis. None of the predictors (clinical score, right,
and left stimulation sites) were significantly correlated with each
other. The regression model was significant [F(2,21) = 5.98, P =
0.009; adjusted R2 = 0.302; information criterion = 142.4] and
retained the right STN site (coefficient=−20.034, t =−2.482, P
= 0.022) and clinical score (coefficient = −3.540, t = −2.134, P
= 0.045) as predictors, but rejected the left STN site. The model
automatically merged the dorsal and central stimulation sites into
a single region for the right STN predictor. Overall, the site of
stimulation in the right STN had greater importance than the
clinical score (0.575 vs. 0.425) as a predictor of optimal frequency.
DISCUSSION
In this study, we aimed to measure the effect of STN-DBS
frequency on gait in finer detail than achieved previously.
Our method was founded on measurements of gait variables
over repeated stride cycles that reflect the performance of
over-ground walking in PD. Stride length captured the small
steps commonly observed in PD gait (21–23), stride velocity
reflected bradykinesia, double-support time detected hesitations
and freezing episodes (17), and step-length asymmetry captured
the left-right asymmetry often observed in PD (19, 24). We
explored a wide range of STN-DBS frequencies with the aim of
finding the acute optimal stimulation frequency, in most cases
with a resolution of 20Hz, for each patient during withdrawal
of their medication (≥12 h). Because of time constraints, this
study did not additionally evaluate the effects of switching off the
stimulator, but this did not detract from the aim of identifying
the optimal frequency for a patient. The optimal frequency varied
considerably between patients, but did not conform to the simple
bimodal frequency distribution (high vs. low frequency) often
implied in the literature (11–13, 16, 25–27). Instead, optimal
frequencies were distributed continuously from 60 to 140Hz. The
principle used for determining an optimal frequency was that it
should be no worse than any other frequency for all gait variables.
This ensured that a frequency was not chosen if it improved
one aspect of gait, but produced a decrement in performance
for another aspect. Furthermore, this had to be the case when
walking either without obstruction or when passing through a
narrow doorway, a condition that has been shown to evoke gait
difficulties in PD (17, 18). Satisfaction of these stringent criteria
resulted in convergence on a single optimal frequency for around
80% of the patients. It is possible that a frequency resolution even
finer than 20Hz could have been established with this algorithm.
However, the fact that we were unable to distinguish between two
or three frequencies in 5 patients implied that we were close to the
limit of practical frequency resolution.
Is Frequency or Voltage the Important
Stimulation Parameter?
Gait performance is described here as a function of STN-
DBS frequency. However, a change in frequency was always
accompanied by a change in stimulation voltage, in order to
satisfy the criterion of constant energy stimulation. Was gait
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performance being altered by changes in voltage or frequency? To
answer this definitively it would be necessary to map gait changes
across a large number of frequency-voltage combinations. This
would not be practically achievable in one session if sufficient
time were allowed to elapse after a change in DBS settings
(30min in the current study) to achieve a stable behavioral effect
(28). Our reduced version of this procedure showed that for
four frequency-voltage combinations, frequency change affected
gait performance more than voltage change. This suggests that
frequency was likely to have been the more critical parameter
across the range of settings that were employed in the study.
What Are the Sources of
Optimal-Frequency Variation?
The patient’s clinical profile is one possible source of variation
of optimal frequency. Previous studies have described the
emergence of axial symptoms in chronically stimulated PD
patients and how these symptoms are often not well-controlled
by the typical high stimulation frequencies employed initially
after surgery (11–14). We therefore investigated whether there
was a relationship between the severity of axial symptoms
measured clinically, or their rate of emergence, and the optimum
frequency for gait. For both measures we found a significant
negative correlation indicating that those patients with more
severe and/or with a faster rate of emergence of axial symptoms
tended to optimize at a lower frequency.
Khoo and colleagues showed a relationship between electrode
contact within the STN and the preferred frequency of
stimulation (11). Using a criterion of the best UPDRS-III score,
they found that in 36% of cases, a patient’s optimum electrode
contact for 60Hz stimulation in the STN was located more
ventrally than his or her optimum contact for 130Hz stimulation.
This raised the possibility that the different frequency-gait
tuning curves between our patients could have been related to
differences in the location of the electrode contact within the
STN. We did indeed find a relationship between the dorsal-
to-ventral active contact location and optimal frequency, but
our results are at odds with those of Khoo and colleagues (11).
We found that dorsal sites were associated with low frequencies
(median 90Hz) and ventral sites with high frequencies (median
120Hz). Our data, however, are consistent with the findings
obtained by Xie and colleagues when they investigated the
effect of STN stimulation through dorsal contacts in two
patients with severe freezing of gait (27). They found that
60Hz stimulation improved the patients’ freezing of gait whereas
130Hz stimulation made it worse.
The two key factors of stimulation site and severity of
clinically assessed postural symptoms were unrelated. This is
understandable given that electrode contact site was determined
shortly after implantation based on effectiveness of improving
overall clinical state, whereas the score considered here is just
one sub-component of clinical state that was measured 4 or more
years later at the time of testing. Nonetheless, both turned out
to be significant predictors of the optimal frequency for gait
when subjected to a multiple regression analysis. However, we
found that the right STN stimulation site was a more important
predictor of optimal frequency than the severity of symptoms.
It is not clear why only the electrode site in the right STN
was retained in the regression model; we were unable to find
any conclusive evidence relating it to asymmetrical severity
of symptoms.
Why Should Optimal Frequencies Differ
Between Patients?
One speculation for between-patient variation in optimal
frequency is that a contribution to axial symptoms arises from the
development of additional pathology outside the basal ganglia. A
candidate is the pedunculopontine nucleus (PPN), which suffers
significant cholinergic cell loss in PD (29). Experimental lesions
of cholinergic PPN neurones in monkeys result in gait changes
characterized by decreased step length and speed (30). Moreover,
a PET study on imagined gait in PD suggested that STN-DBSmay
improve parkinsonian gait by modulating brainstem locomotor
centers including the PPN (31). Presumably, additional PPN
pathology would produce a greater gait disturbance in PD than
pathology restricted to the basal ganglia. DBS applied directly
to the PPN has been shown to improve motor function in
some of the small number of patients in which it has been
attempted, but the therapeutic frequency is generally less than
that used for STN-DBS, ranging from 10 to 70Hz (32–36).
The STN connects with the PPN as well as the other basal
ganglia nuclei in man (37), and so would be capable of exerting
influence on both putative lesioned circuits. However, the STN-
DBS frequency required may differ for the two circuits with a
low frequency for the PPN and a high frequency for the basal
ganglia. The optimal frequency for gait may be a compromise
between a high and low frequency depending on the relative
disruption of function caused by each of the two lesions. Such a
mechanism could explain why the optimal frequency for gait was
continuously distributed between 60 and 140Hz in our cohort. It
also provides an explanation for why patients with greater axial
symptoms, arguably implying greater PPN disruption, tend to
optimize at a lower frequency. However, it is not clear whether
this model can also explain why active electrode contacts located
in the dorsal STN should favor lower frequencies compared to
ventral contacts. One possibility could be that STN projections
to PPN are not uniformly distributed throughout the STN, but
have stronger connections in more dorsal regions. More detailed
neuro-anatomy of these regions inman than is currently available
would be required to investigate this hypothesis.
Study Limitations
In this study, we chose to use a reduced version of the UPDRS-
III test as a clinical assessment of axial symptoms. Other clinical
tests may be considered more comprehensive in their analysis
of the different postural domains affected, but our choice of test
was limited by the time constraints of the demanding protocol
and to enable comparisons with prior clinical assessments of
axial function in the same patients. The rater for the clinical
assessment of axial function was an experienced clinician, but
was not blinded to stimulation condition. Although this is
a limitation, it was an inevitable consequence of the same
clinician being responsible for setting the DBS parameters. The
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second experiment, which investigated the relative effect of
stimulation voltage and frequency on gait performance, had
limitations as it was undertaken and completed by only 42% of
the group and four representative voltage-frequency conditions
were mapped, out of all possible combinations. Finally, the
quantitative assessment of DBS frequency on gait performance
was performed over a short time-scale, i.e., started 30min after
a change in stimulation setting and completed within 30min
(60min in total). Whether, the measured gait performance at a
given frequency keeps stable over a longer time-scale remains an
open question.
CONCLUSION
In conclusion, the gait performance of PD patients receiving
STN-DBS for four or more years was sensitive to relatively
small changes in stimulation frequency. In 79% of patients it
was possible to determine statistically an optimum frequency for
each individual’s gait performance with a resolution of 20Hz.
The optimum frequency varied considerably between patients
and was associated with both the dorsal-ventral location of the
electrode contact site and the severity of their axial symptoms.
This variability may stem from variable progression of pathology
outside the basal ganglia.
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